Table 1.
Baseline patient characteristics
| Characteristics | Full cohort, N=114a n (%) |
|---|---|
| Age (years) | |
| ≥50 | 14 (12) |
| 36–49 | 43 (38) |
| ≤35 | 57 (50) |
| Sex | |
| Male | 85 (75) |
| Female | 29 (25) |
| Body mass index (BMI) | |
| BMI ≥19 kg/m2 | 97 (89) |
| BMI<19 kg/m2 | 12 (11) |
| White blood cell (WBC) count | |
| WBC>9100 cells/mm3 | 14 (13) |
| 3100 cells/mm3≤WBC≤9100 cells/mm3 | 85 (82) |
| WBC<3100 cells/mm3 | 5 (5) |
| Haemoglobin (Hgb) | |
| Hgb ≥9.5 g/dL | 72 (70) |
| Hgb<9.5 g/dL | 31 (30) |
| ART status at enrolment | |
| Already on ART at enrolment | 104 (96) |
| Started ART at enrolment | 4 (4) |
| Duration on ART prior to first chemotherapy dose (days) | |
| ART duration>180 | 33 (32) |
| 30<ART duration ≤180 | 45 (44) |
| ART duration ≤30 | 24 (24) |
| Indication for ART | |
| WHO stage IV condition – KS | 65 (64) |
| WHO stage III condition (excluding TB) | 16 (16) |
| CD4 count<250 (cells/mm3) | 11 (11) |
| WHO stage III – TB | 6 (6) |
| Other WHO stage IV condition | 3 (3) |
| ART regimen at enrolment | |
| NVP/3TC/d4T | 105 (97) |
| NVP/3TC/AZT | 2 (2) |
| LPV/r+AZT/3TC/TDF | 1 (1) |
| KS T stage (ACTG) at enrolment | |
| T1b | 103 (97) |
| T0 | 3 (3) |
a
Values that do not sum to 114 reflect missing data
b
T1: oedema or ulceration, extensive oral mucosa KS, or visceral KS; indicates ACTG “Poor Risk” disease.
ART: antiretroviral therapy; NVP/3TC/d4T: nevirapine/lamivudine/stavudine; NVP/3TC/AZT: nevirapine/lamivudine/zidovudine; LPV/r+AZT/3TC/TDF: lopinavir/ritonavir+zidovudine/lamivudine/tenofovir; T stage: tumour extent; ACTG: AIDS Clinical Trials Group staging.